Novartis AG (LON:0QLR)

London flag London · Delayed Price · Currency is GBP · Price in CHF
105.66
+1.41 (1.35%)
At close: Oct 3, 2025
1.35%
Market Cap190.10B
Revenue (ttm)40.28B
Net Income (ttm)9.97B
Shares Outn/a
EPS (ttm)5.00
PE Ratio19.07
Forward PE15.09
Dividend3.07 (2.95%)
Ex-Dividend DateMar 11, 2025
Volume933,507
Average Volume1,132,985
Open104.38
Previous Close104.25
Day's Range104.40 - 106.16
52-Week Range81.22 - 105.66
Beta0.57
RSI72.47
Earnings DateOct 28, 2025

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]

Industry Pharmaceutical Preparations
Founded 1996
Employees 75,883
Stock Exchange London Stock Exchange
Ticker Symbol 0QLR
Full Company Profile

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.